Samsung BioLogics

Samsung Biologics, founded in April 2011 and headquartered in Incheon, South Korea, is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry. Established by key players within the Samsung Group and Quintiles Transnational Corp, the company aims to provide high-quality, innovative, and efficient services to its global clients, with Europe and the United States accounting for 90% of its revenue. Samsung Biologics offers comprehensive development and manufacturing services, spanning from cell line development to final commercial production, and boasts a total production capacity of 604,000 liters, one of the largest worldwide. The company's CDMO services represent 72.4% of its revenue, while the remainder comes from its subsidiary, Samsung Bioepis, which focuses on developing and manufacturing biosimilars. The organization emphasizes strict adherence to quality and regulatory standards, ensuring compliance with international cGMP requirements. Dr. Tae Han Kim, the Chief Executive Officer, has played a significant role in the company’s expansion and operational excellence since joining Samsung in 1979.

John Rim

CEO and President

2 past transactions

C2N Diagnostics

Corporate Round in 2025
Founded in 2007 by scientists from Washington University School of Medicine and LifeTech Research, C2N Diagnostics specializes in protein diagnostic testing services for neurological disorders. Utilizing mass spectrometry-based analysis, the company aims to provide accurate and sensitive diagnostics for conditions like Alzheimer's disease.

Samsung Bioepis

Acquisition in 2022
Samsung Bioepis Co., Ltd. is a biopharmaceutical company based in Incheon, South Korea, specializing in the development and production of biosimilar products. Established in 2012, the company aims to enhance patient access to high-quality treatment options through its extensive pipeline of biosimilar candidates. Samsung Bioepis focuses on innovative therapies targeting various health conditions, including neurodegenerative diseases, hemophilia, and autoimmune disorders. The company has formed a strategic collaboration with Takeda Pharmaceutical Company, further strengthening its position in the biopharmaceutical industry. By leveraging process innovation, Samsung Bioepis strives to provide improved healthcare solutions for patients worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.